Click to go to DrugInjuryLaw Home


Legal information and news about prescription drug side effects
NuvaRing Case Evaluation Ortho Evra Case Evaluation Fosamax Case Evaluation Avandia Case EvaluationKetek Case Evaluation Zelnorm Case Evaluation Meridia Case Evaluation Zocor Case Evaluation
Vytorin Case EvaluationZetia Case Evaluation Yasmin Case Evaluation Ocella Case EvaluationYAZ Case Evaluation Levaquin Case Evaluation Byetta Case Evaluation Gianvi Case Evaluation


Free Case Evaluation

First NuvaRing Lawsuit Trials Against Merck Are Currently Scheduled To Start In May 2013 (New Jersey State Court NuvaRing Mass Tort Consolidation) And July 2013 (Federal Court NuvaRing MDL)

These Bellwether Trials Will Serve As Test Cases For The More Than 1000 Filed Legal Claims Concerning Blood Clot Side Effects Such As Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT), Stroke, And Heart Attack Or Myocardial Infarction

UPDATE: On March 5, 2013 Judge Martinotti moved the first New Jersey state court NuvaRing trial to June 17, 2013 at the request of the defense attorneys.

It is anticipated that, in turn, Judge Sippel will move back the start date for the first federal court NuvaRing MDL trial from July 2013 to August 2013.

(3/6/13)


 

The first bellwether, or test, trial in the New Jersey state court consolidation of NuvaRing lawsuits is currently scheduled to start on May 6, 2013. The first trial will be picked from a group of nine "eligible" bellwether cases, seven of which are pulmonary embolism (PE) cases (one PE resulted in a death) and two of which are stroke cases.

In the federal court NuvaRing MDL, the first bellwether trial is set to start on July 8, 2013. The eligible set of cases there are pulmonary embolism (PE) cases but for two stroke cases, and all injury (not death) cases.

The outcome of those bellwether case trials will have a great influence on how the rest of the NuvaRing cases will be resolved.

If the initial set of these trials go in the favor of the women who have suffered serious blood clot related medical conditions and the jury verdicts are significant in amount, it is likely that the Defendant drug company Merck will seek to establish some sort of settlement plan for the remaining 1000 plus lawsuits that have been filed to date.

On the other hand, if those early trials result in defense verdicts, there will be very little incentive for the Defendant Merck to pay any substantial legal compensation in order to settle the remaining cases.

We have been handling NuvaRing lawsuits since 2007.

To find out if you may have a personal injury or wrongful death NuvaRing case, you can either call attorney Tom Lamb at 800-426-9535 or use our free online NuvaRing Case Evaluation for blood clot side effects such as pulmonary embolism (PE), deep vein thrombosis (DVT), stroke, and myocardial infarction (MI) or heart attack.

Go to Free NuvaRing Case Evaluation form >>

Read more on the NuvaRing Information Page >>

All content by attorney Tom Lamb


  • US FDA advises that you should not stop taking any prescription medication before talking to your doctor.
  • Reports of serious drug side effects should be made to the US FDA MedWatch program.
  • The prescription drug names are registered trademarks of the respective drug companies.
  • DrugInjuryLaw.com is not affiliated with any of the drug companies, nor US FDA.
Law Offices of Thomas J. Lamb, P.A.
Lumina Station Suite 225
1908 Eastwood Road
Wilmington, NC 28403
Tel: (910) 256-2971   Fax: (910) 256-2972
Toll Free: (800) 426-9535
email: ThomasJLamb@DrugInjuryLaw.com

Disclaimer